577 related articles for article (PubMed ID: 19961929)
61. Doxorubicin-loaded glycyrrhetinic acid modified recombinant human serum albumin nanoparticles for targeting liver tumor chemotherapy.
Qi WW; Yu HY; Guo H; Lou J; Wang ZM; Liu P; Sapin-Minet A; Maincent P; Hong XC; Hu XM; Xiao YL
Mol Pharm; 2015 Mar; 12(3):675-83. PubMed ID: 25584860
[TBL] [Abstract][Full Text] [Related]
62. Bromelain-decorated hybrid nanoparticles based on lactobionic acid-conjugated chitosan for in vitro anti-tumor study.
Wei B; He L; Wang X; Yan GQ; Wang J; Tang R
J Biomater Appl; 2017 Aug; 32(2):206-218. PubMed ID: 28618976
[TBL] [Abstract][Full Text] [Related]
63. Enhanced Cellular Cytotoxicity and Antibacterial Activity of 18-β-Glycyrrhetinic Acid by Albumin-conjugated PLGA Nanoparticles.
Darvishi B; Manoochehri S; Esfandyari-Manesh M; Samadi N; Amini M; Atyabi F; Dinarvand R
Drug Res (Stuttg); 2015 Dec; 65(12):617-23. PubMed ID: 25607747
[TBL] [Abstract][Full Text] [Related]
64. Formulation and optimization of doxorubicin loaded polymeric nanoparticles using Box-Behnken design: ex-vivo stability and in-vitro activity.
Shaikh MV; Kala M; Nivsarkar M
Eur J Pharm Sci; 2017 Mar; 100():262-272. PubMed ID: 28126560
[TBL] [Abstract][Full Text] [Related]
65. Poly(L-lactide)-vitamin E TPGS nanoparticles enhanced the cytotoxicity of doxorubicin in drug-resistant MCF-7 breast cancer cells.
Li PY; Lai PS; Hung WC; Syu WJ
Biomacromolecules; 2010 Oct; 11(10):2576-82. PubMed ID: 20722436
[TBL] [Abstract][Full Text] [Related]
66. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
[TBL] [Abstract][Full Text] [Related]
67. Folate-containing reduction-sensitive lipid-polymer hybrid nanoparticles for targeted delivery of doxorubicin.
Wu B; Yu P; Cui C; Wu M; Zhang Y; Liu L; Wang CX; Zhuo RX; Huang SW
Biomater Sci; 2015 Apr; 3(4):655-64. PubMed ID: 26222425
[TBL] [Abstract][Full Text] [Related]
68. Facile Layer-by-Layer Self-Assembly toward Enantiomeric Poly(lactide) Stereocomplex Coated Magnetite Nanocarrier for Highly Tunable Drug Deliveries.
Li Z; Yuan D; Jin G; Tan BH; He C
ACS Appl Mater Interfaces; 2016 Jan; 8(3):1842-53. PubMed ID: 26717323
[TBL] [Abstract][Full Text] [Related]
69. Charge-conversional and reduction-sensitive poly(vinyl alcohol) nanogels for enhanced cell uptake and efficient intracellular doxorubicin release.
Chen W; Achazi K; Schade B; Haag R
J Control Release; 2015 May; 205():15-24. PubMed ID: 25445693
[TBL] [Abstract][Full Text] [Related]
70. Real-time imaging tracking of a dual-fluorescent drug delivery system based on doxorubicin-loaded globin- polyethylenimine nanoparticles for visible tumor therapy.
Zhang Y; Wei C; Lv F; Liu T
Colloids Surf B Biointerfaces; 2018 Oct; 170():163-171. PubMed ID: 29906701
[TBL] [Abstract][Full Text] [Related]
71. A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery.
Liu P; Yu H; Sun Y; Zhu M; Duan Y
Biomaterials; 2012 Jun; 33(17):4403-12. PubMed ID: 22436800
[TBL] [Abstract][Full Text] [Related]
72. Enhanced cellular uptake of folic acid-conjugated PLGA-PEG nanoparticles loaded with vincristine sulfate in human breast cancer.
Chen J; Li S; Shen Q; He H; Zhang Y
Drug Dev Ind Pharm; 2011 Nov; 37(11):1339-46. PubMed ID: 21524153
[TBL] [Abstract][Full Text] [Related]
73. N-Acetyl-D-glucosamine decorated polymeric nanoparticles for targeted delivery of doxorubicin: Synthesis, characterization and in vitro evaluation.
Tian B; Ding Y; Han J; Zhang J; Han Y; Han J
Colloids Surf B Biointerfaces; 2015 Jun; 130():246-54. PubMed ID: 25921641
[TBL] [Abstract][Full Text] [Related]
74. Nuclear targeting peptide-modified, DOX-loaded, PHBV nanoparticles enhance drug efficacy by targeting to Saos-2 cell nuclear membranes.
Şahin A; Eke G; Buyuksungur A; Hasirci N; Hasirci V
J Biomater Sci Polym Ed; 2018 Apr; 29(5):507-519. PubMed ID: 29297759
[TBL] [Abstract][Full Text] [Related]
75. Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles.
Chittasupho C; Lirdprapamongkol K; Kewsuwan P; Sarisuta N
Eur J Pharm Biopharm; 2014 Oct; 88(2):529-38. PubMed ID: 25119723
[TBL] [Abstract][Full Text] [Related]
76. Co-delivery nanoparticles of doxorubicin and chloroquine for improving the anti-cancer effect in vitro.
Sun JH; Ye C; Bai EH; Zhang LL; Huo SJ; Yu HH; Xiang SY; Yu SQ
Nanotechnology; 2019 Feb; 30(8):085101. PubMed ID: 30523865
[TBL] [Abstract][Full Text] [Related]
77. Hypoxia-responsive polymeric nanoparticles for tumor-targeted drug delivery.
Thambi T; Deepagan VG; Yoon HY; Han HS; Kim SH; Son S; Jo DG; Ahn CH; Suh YD; Kim K; Kwon IC; Lee DS; Park JH
Biomaterials; 2014 Feb; 35(5):1735-43. PubMed ID: 24290696
[TBL] [Abstract][Full Text] [Related]
78. Zirconium phosphate nanoplatelets: a biocompatible nanomaterial for drug delivery to cancer.
Saxena V; Diaz A; Clearfield A; Batteas JD; Hussain MD
Nanoscale; 2013 Mar; 5(6):2328-36. PubMed ID: 23392208
[TBL] [Abstract][Full Text] [Related]
79. Doxorubicin-Loaded Carborane-Conjugated Polymeric Nanoparticles as Delivery System for Combination Cancer Therapy.
Xiong H; Zhou D; Qi Y; Zhang Z; Xie Z; Chen X; Jing X; Meng F; Huang Y
Biomacromolecules; 2015 Dec; 16(12):3980-8. PubMed ID: 26564472
[TBL] [Abstract][Full Text] [Related]
80. Modified methods of nanoparticles synthesis in pH-sensitive nano-carriers production for doxorubicin delivery on MCF-7 breast cancer cell line.
Hamidu A; Mokrish A; Mansor R; Razak ISA; Danmaigoro A; Jaji AZ; Bakar ZA
Int J Nanomedicine; 2019; 14():3615-3627. PubMed ID: 31190815
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
